Axsome Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Axsome Therapeutics's estimated annual revenue is currently $4.8M per year.
- Axsome Therapeutics received $24.0M in venture funding in March 2019.
- Axsome Therapeutics's estimated revenue per employee is $6,884
- Axsome Therapeutics's total funding is $207M.
Employee Data
- Axsome Therapeutics has 698 Employees.
- Axsome Therapeutics grew their employee count by 27% last year.
Axsome Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Executive Coordinator and Assistant to the CEO | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | Head HEOR | Reveal Email/Phone |
6 | VP Program Management | Reveal Email/Phone |
7 | VP Clinical & Regulatory | Reveal Email/Phone |
8 | General Counsel | Reveal Email/Phone |
9 | VP Medical Affairs | Reveal Email/Phone |
10 | SVP, Clinical Development & Medical Affairs s | Reveal Email/Phone |
Axsome Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 3 | 0% | N/A | N/A |
#2 | N/A | 20 | 43% | N/A | N/A |
#3 | $6.7M | 33 | -6% | N/A | N/A |
#4 | $34.4M | 222 | -1% | N/A | N/A |
#5 | $5.2M | 67 | 0% | $10M | N/A |
#6 | $2M | 13 | 0% | N/A | N/A |
#7 | $7.5M | 37 | 0% | $51.6M | N/A |
#8 | $0.3M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 21 | -16% | $3.3M | N/A |
#10 | $3.6M | 20 | 5% | N/A | N/A |
What Is Axsome Therapeutics?
Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of CNS disorders. Axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. The company is based in New York City.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$207M
Total Funding
698
Number of Employees
$4.8M
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Axsome Therapeutics News
Shares of Axsome Therapeutics Inc. rose more than 20% on Tuesday after the biopharmaceutical company reported positive developments in its...
The stock price of Axsome Therapeutics Inc (NASDAQ: AXSM) increased by over 25% pre-market today. Investors are responding positively to...
AXS-05 could be the first drug developed by Axsome Therapeutics to reach commercialization, but it probably won't become the company's first...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $115.4M | 699 | -2% | $112M |
#2 | $225M | 700 | 7% | N/A |
#3 | $183.8M | 700 | N/A | N/A |
#4 | $249.3M | 701 | 23% | N/A |
#5 | $339.4M | 701 | 6% | N/A |
Axsome Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-11-11 | $20.0M | Undisclosed | Silicon Valley Bank | Article |
| 2017-12-04 | $9.5M | Undisclosed | H.C. Wainwright & Co | Article |
| 2019-03-07 | $24.0M | Undisclosed | Silicon Valley Bank | Article |